ArticleTranslational pediatrics2025
Screening for biomarkers of bronchopulmonary dysplasia: a bioinformatics analysis.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bronchopulmonary dysplasia (BPD) is a common chronic respiratory disease in preterm infants, and its incidence has gradually increased with advances in medical technology. BPD is associated with multiple complications, significantly impacting the quality of life of affected infants and imposing substantial economic burdens on families and society. Currently, the molecular mechanisms of BPD are not fully understood, and effective treatments are lacking. MicroRNAs (miRNAs), as important gene regulatory molecules, play a critical role in lung development and BPD. This study aims to investigate the potential role of miRNAs in BPD, with a particular focus on miR-9-5p and guanosine triphosphate cyclohydrolase 1 (GCH1). Methods: Differential expression analysis of genes and miRNAs was conducted using the Gene Expression Omnibus (GEO) database. A hyperoxia-induced injury cell model was constructed to examine the expression of miR-9-5p. Target genes of miR-9-5p were predicted using online databases, followed by functional and protein interaction network analyses. In addition, cell culture, real-time quantitative polymerase chain reaction (RT-qPCR), western blotting, reactive oxygen species (ROS) level detection, malondialdehyde (MDA) assay, and Fe Results: In the GSE108755 dataset, miR-9-5p was found to be upregulated in the blood of infants with BPD. In the hyperoxia-induced injury cell model, miR-9-5p expression was significantly increased. GCH1 was identified as a target gene through intersection with ferroptosis regulatory gene sets. In the cell model, GCH1 expression was markedly downregulated, while ROS, MDA, and Fe Conclusions: This study provides new insights into the molecular mechanisms of BPD, suggesting that miR-9-5p and GCH1 may serve as potential therapeutic targets for BPD. The findings contribute to a deeper understanding of the molecular basis of BPD, providing theoretical and experimental support for its diagnosis and treatment strategies. Future research will further explore the regulatory relationship between miR-9-5p and GCH1 and their roles in animal models, cell models, and clinical patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.